A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer

Anti-Cancer Drugs

Volumn 12, Issue 6, 2001, Pages 533-540

  Li, N ^a   Van Agthoven, M ^a   Willemse, P H B ^b   Uyl De Groot, C A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness analysis; Cost utility analysis; Decision model; Docetaxel; Metastatic breast cancer; Paclitaxel; Quality adjusted life years; Second line chemotherapy; Vinorelbine

Indexed keywords

DOCETAXEL; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINBLASTINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; COST UTILITY ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; FLUID RETENTION; HUMAN; LIFE EXPECTANCY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MITOMYCIN; MODELS, STATISTICAL; NEOPLASM METASTASIS; QUALITY OF LIFE; TIME FACTORS; VINBLASTINE;

EID: 0034915869     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200107000-00007     Document Type: Article

References (34)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Improvement in the prognosis of breast cancer from 1965 to 1984
4. Metastatic breast cancer: The role of chemotherapy
5. Optimizing chemotherapy for patients with advanced breast cancer
6. Kinetic concepts in the systemic drug therapy of breast cancer
7. Paclitaxel plus nonanthracycline combinations in metastatic breast cancer
8. Consensus Summary on Breast Cancer
9. Evolution in the treatment of advanced breast cancer
10. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer, a prospective randomized trial
11. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer. A Vanderbilt Cancer Center phase II trial
12. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer, results of a clinical phase II study
13. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: A phase II trial
14. Current management of advanced breast cancer
15. Future directions for vinorelbone (Navelbine)
16. Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer
17. The current state of adjuvant therapy for breast cancer: Focus on paclitaxel
18. Docetaxel, a pharmacoeconomic review of its use in the treatment of metastatic breast cancer
19. Phase II trial of navelbine and fluorouracil as second-line chemotherapy in metastatic breast carcinoma
20. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and 1-leucovorin plus human granulocyte colony-stimulating factor
21. A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer
22. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer
23. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer
24. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine
25. Cost-utility analysis of taxane therapy
26. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia
27. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
28. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
29. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: A two-stage phase 2 study
30. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients
31. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer: A phase II study
32. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer